Figure 1From: Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry Cost-effectiveness planes of 1000 bootstrap replicates of the incremental cost and effectiveness (based on the number of patients in remission, defined as a Disease Activity Score in 28 joints < 2.6) of the treat-to-target strategy versus usual care in early rheumatoid arthritis after A) two years and B) three years of follow-up. Back to article page